Skip to main content
    R

    Rxsight Inc (RXST)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.30
    -0.02 (-0.38%)

    Market Cap: $223.06M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rxsight Inc (RXST) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Rxsight (RXST) trades at 1.8x sales and 0.9x book value. Its P/S of 1.8x is below its 5-year median of 7.9x. Its forward P/E is 116.3x.

    Current Multiples

    Its free cash flow yield is 8.4%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E116.3x
    Price to sales1.8x
    Price to book0.9x
    Price to FCF11.9x
    EV/FCF8.7x
    PEGN/A
    FCF yield8.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S1.8x7.9xN/A
    P/B0.9x3.6xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 5 year ends shown, its P/S ranged from 3.2x in 2025 to 15.7x in 2023. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$10.423.2x1.6x
    2024$34.389.6x4.9x
    2023$40.3215.7x9.0x
    2022$12.677.2x3.9x
    2021$11.255.6x2.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RXST

    What is RXST's forward P/E ratio?

    Rxsight has a forward P/E ratio of 116.3x.

    Is RXST stock overvalued?

    GNG's valuation label for RXST is Undervalued.

    What is RXST's price to sales ratio?

    Rxsight has a price to sales ratio of 1.8x.